Form 4 for RCUS Arcus Biosciences, Inc.
Accepted 2025-10-08 00:00:00 ET · period of report 2025-10-06 · accession 0001671311-25-000003 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2025-10-08 | 2025-10-06+ | RCUS | Jarrett Jennifer | COO | M - OptEx | $1.23 | +50.3K | 226.7K | +29% | +$61.9K |
| DM | 2025-10-08 | 2025-10-06+ | RCUS | Jarrett Jennifer | COO | S - Sale+OE | $14.92 | -50.3K | 214.2K | -19% | -$750.5K |
| DM | 2025-10-08 | 2025-10-06+ | RCUS | Jarrett Jennifer | COO | M - OptEx | $0.00 | -50.3K | 130.9K | -28% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-10-08 | M | A | 37,792 | $1.23 | 252,024 | D | — | — | (F1) The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. (F2) Includes 863 shares purchased on 5/30/2025 through the Company's Employee Stock Purchase Plan. |
| 2 | Common | Common Stock | 2025-10-08 | S | D | 37,792 | $15.05 | 214,232 | D | — | — | (F1) The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. (F4) The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.00 to $15.16, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. (F2) Includes 863 shares purchased on 5/30/2025 through the Company's Employee Stock Purchase Plan. |
| 3 | Common | Common Stock | 2025-10-06 | S | D | 12,500 | $14.54 | 214,232 | D | — | — | (F1) The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. (F3) The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.40 to $14.72, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. (F2) Includes 863 shares purchased on 5/30/2025 through the Company's Employee Stock Purchase Plan. |
| 4 | Common | Common Stock | 2025-10-06 | M | A | 12,500 | $1.23 | 226,732 | D | — | — | (F1) The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. (F2) Includes 863 shares purchased on 5/30/2025 through the Company's Employee Stock Purchase Plan. |
| 5 | Derivative | Stock Option (Right to Buy) | 2025-10-06 | M | D | 12,500 | $0.00 | 168,666 | D | $1.23 · — to 2027-03-14 | 12,500 Common Stock | (F5) The option is fully vested and currently exercisable. |
| 6 | Derivative | Stock Option (Right to Buy) | 2025-10-08 | M | D | 37,792 | $0.00 | 130,874 | D | $1.23 · — to 2027-03-14 | 37,792 Common Stock | (F5) The option is fully vested and currently exercisable. |